A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma

doi:10.1158/1078-0432.ccr-19-0836

A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

Aug 22, 2019

Y N Vashisht GopalMichael Q A Davies

PMID: 31439581

DOI: 10.1158/1078-0432.ccr-19-0836

Get paper from

Abstract

The purpose of this study is to determine if inhibition of mitochondrial oxidative phosphorylation (OxPhos) is an effective strategy against MAPK pathway inhibitor (MAPKi)-resistant BRAF-mutant melanomas. The antimelanoma activity of IACS-010759 (OPi), a novel OxPhos complex I inhibitor...read more

Mentioned in this Paper

Energy Transfer

Glutamine

Glycolysis

Melanoma

Mitochondria

Neoplasms

Oxidative Phosphorylation

Positron-Emission Tomography

Internal

Evaluation

Paper Details

References

References
Citations

References currently unavailable
We're still populating references for this paper, please check back later.

References
Citations

No citations available
This paper may not have been cited yet.

Skin Cutaneous Melanoma

Cutaneous melanoma is a cancer of the pigment-producing cells known as melanocytes. While it has a 98 percent five-year survival rate when caught early, thousands of deaths are attributed to this cancer each year. Here is the latest research.

Cancer Genomics

Cancer genomics employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research here.

Metabolomics

Metabolomics refers to the large-scale study of profiling all metabolites in biological systems in a non-targeted manner. Here is the latest research.

G-Protein-Coupled Receptors

G-protein-coupled receptors (GPCRs), the largest family of integral membrane proteins, participate in the regulation of many physiological functions and are the targets of approximately 30% of currently marketed drugs. Here is the latest research.

Counteracting oxidative phosphorylation-mediated resistance of melanomas to MAPK pathway inhibition

Molecular & Cellular OncologyJanuary 23, 2015

Jennifer Leigh McQuade, Y N Vashisht Gopal

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Nature MedicineJune 13, 2018

Jennifer R MolinaJoseph R Marszalek

Contact Help Terms Privacy Cookies

A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma

Abstract